Clinical Trials

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

For women who carry the breast cancer 1 gene mutation. Finding out if removing just the fallopian tubes now and the ovaries later is as good as removing both the tubes and ovaries at the same time for lowering the risk of ovarian cancer in women who have a harmful BRCA1 gene mutation

This study is being done to answer the following question: Can we lower the chance of cancer growing or spreading with the combination of a newer medication and other therapies: We are doing this study because we want to find out if this approach is better or worse than the usual approach for your cancer. The usual approach is defined as care most people get for cancer.

This study is being done to see if adding chemotherapy to the usual treatment for advanced prostate cancer helps patients live longer. The drug is already approved by the FDA for treating prostate cancer. However, it is usually used only after hormonal therapy and apalutamide are no longer working. The study will also look at a test to see if it can help doctors decide which patients might benefit the most from adding the drug. Doctors do not know yet if this test will be useful in making treatment choices. If it is helpful, it could become a regular part of care for men with advanced prostate cancer.

The PROACTIVE-HF-2 Trial is a research study looking at a small device called the Cordella™ Pulmonary Artery Sensor. Doctors use this sensor to check how your heart is working by measuring the pressure in your lungs every day. The goal of the study is to help people with heart failure feel better and stay out of the hospital.

The purpose of this study is to understand if the drug Gleolan can improve the ability to show ovarian cancer tumor tissue and what is the benefit and risk of such during surgery and to understand the safety of the drug Gleolan in patients with ovarian tumors.

(Study is CLOSED at this site) - This study is being done to see if we can possibly shrink or prevent your head and neck cancer from spreading by adding an antibody drug (cetuximab) to your immunotherapy treatment (pembrolizumab).

The purpose of the GORE CARDIOFORM Septal Occluder (GSO Device) post-approval study is to assess the safety and effectiveness of GSO device as observed in the REDUCE pivotal IDE study, and to evaluate the quality of the operator education and training and transferability of trial experience to a post-market setting.

The purpose of this study is to compare a usual treatment alone to using MEDI4736 (durvalumab) plus the usual treatment. The study approach could shrink your cancer. But, it could also cause side effects, which are described in the risks section below. MEDI4736 (durvalumab) is a type of immunotherapy drug that is already approved by the FDA for use in urothelial cancer. But, most of the time it is not used until platinum-containing chemotherapy, such as cisplatin, stops working for your cancer. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking at two main factors. They will be investigating if the study approach will increase the number of patients whose cancer is shrunk significantly after surgery. They will also be investigating if the study approach increases the number of patients who do not have the cancer come back or get worse.

Demonstrate the effectiveness of LAA exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for artial fibrillation and ischemic stroke